Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
Launched by THE CLEVELAND CLINIC · Nov 13, 2023
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two medications, sugammadex and neostigmine, to see which one is more effective at reversing a type of muscle relaxation caused by a drug called rocuronium. This muscle relaxation is often necessary during a procedure called endoscopic retrograde cholangiopancreatography (ERCP), which helps doctors examine the bile ducts. The study is taking place at Cleveland Clinic and is open to adults aged 18 and older who are in certain health categories.
To participate, individuals must be scheduled for the outpatient ERCP procedure and meet specific health requirements, such as not having certain neuromuscular disorders or severe kidney disease. Participants will be randomly assigned to receive either sugammadex or neostigmine, and neither they nor the researchers will know which medication they are receiving to ensure fairness in the results. This trial aims to improve the safety and effectiveness of muscle relaxation reversal in patients undergoing this procedure, ultimately benefiting future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥18 years old
- • American Society of Anesthesiologist physical status 3-4
- • Scheduled for outpatient endoscopic retrograde cholangiopancreatography
- Exclusion Criteria:
- • Difficult Airway
- • Neuromuscular Disorders (eg: ALS, Botulism, Myasthenia Gravis, Lambert-eaton syndrome)
- • End stage renal disease requiring dialysis
- • Pregnancy or breast-feeding
- • Allergy to Fentanyl
- • Allergy to Neuromuscular blocking drugs (eg: rocuronium)
- • Allergy to Neuromuscular reversal drugs (eg: sugammadex or neostigmine)
- • Allergy to glycopyrrolate
About The Cleveland Clinic
The Cleveland Clinic is a renowned nonprofit academic medical center based in Cleveland, Ohio, recognized for its commitment to advancing healthcare through innovative research and clinical excellence. As a leading sponsor of clinical trials, the Cleveland Clinic leverages its multidisciplinary expertise and state-of-the-art facilities to conduct groundbreaking studies aimed at improving patient outcomes across a wide range of medical conditions. With a strong emphasis on patient-centered care, the institution fosters collaboration among researchers, clinicians, and patients to explore new treatments and therapies, contributing significantly to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Cleveland, Ohio, United States
Patients applied
Trial Officials
Ryu Komatsu, MD
Principal Investigator
The Cleveland Clinic
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported